Drug Topics August 3, 2024
These therapies are highly beneficial, but can come with a host of gastrointestinal adverse effects that patients may not be prepared to manage alone.
Robert Kushner, MD, MS, professor of medicine and medicine education at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, sat down with Drug Topics ahead of the American Society for Preventive Cardiology Congress on CVD Prevention to discuss the benefits of glucagon-like peptide-1 (GLP-1) therapies and highlighted some strategies for management of adverse effects.
Drug Topics: What patient populations are most likely to benefit from glucagon-like peptide-1 (GLP-1) receptor agonists for obesity management, and what criteria should be considered when recommending these medications?
Robert Kushner, MD, MS: Incretin-based medications, such as GLP-1s or glucose-dependent...
Today's Sponsors
Today's Sponsor